Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260104 | 1.00 | MCHR1 (0.68) | MCHR1OPRM1MEN1KMT2ACCR8 | |
| SCHEMBL5884259 | 0.82 | MCHR1 (0.76) | MCHR1 | |
| SCHEMBL5884440 | 0.81 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5884277 | 0.81 | MCHR1 (0.90) | MCHR1 | |
| SCHEMBL7260093 | 0.78 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5884214 | 0.78 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5883841 | 0.78 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL7259172 | 0.77 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5884140 | 0.77 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5883856 | 0.76 | MCHR1 (0.88) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989392-B2 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBOTT LABORATORIES (US) | 2006-01-24 | — | — | US | claimed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | claimed |
| US-6989392-B2 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBOTT LABORATORIES (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003105850-A1 | 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063756-A1 | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists | MCHR1, MCHR2, MC1R | MCHR1 1/4885OPRM1 110/4885MEN1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.